

Virginia Medicaid
Pharmacy & Therapeutics Committee Meeting
Agenda
600 East Broad Street – 1st Floor Conference Rooms
Richmond, VA 23219
Thursday, March 17, 2022 – 10 AM

Welcome and Comments	Chethan Bachireddy, MD, CMO, Chair
Call to Order	Chethan Bachireddy, MD, CMO, Chair
Drug Utilization Review (DUR) Board Report	Rachel Cain, PharmD
Approval of Minutes from September 14th and 27th, 2021, Meeting	P&T Committee Members
PDL (PREFERRED DRUG LIST) Management	P&T Committee Members
PDL Phase I – New Drug Review (<i>Therapeutic Class</i>)	

Brand Drugs

- Eprontia™ Solution (Anticonvulsants) **Closed Class**
- Bylvay™ and Livmarli™ (Bile Salts)
- Skytrofa™ (Growth Hormone) **Closed Class**
- Apretude® (HIV PrEP) **Closed Class**
- Opzelura™ (Atopic Dermatitis) **Closed Class**
- Tyrvaya™ Nasal Spray (Ophthalmic, Anti-Inflammatory/Immunomodulators-Type) **Closed Class**
- Vuity™ eye drop (Ophthalmic, Glaucoma Agents)
- Leqvio® (Lipotropics, Others)
- Tarpeyo™ (Glucocorticoids, Oral)

Generics Drugs or New Dosage Forms

- Nebivolol, new generic for Bystolic® (Beta Blockers)
- Mavyret®, Epclusa®, new Pellet packs (Hepatitis C Agents) **Closed Class**
- Rosuvastatin-Ezetimibe, new generic for Roszet® (Lipotropics, Statins)
- Maraviroc, new generic for Selzentry® (HIV) **Closed Class**
- Brimonidine-Timolol, new generic for Combigan® (Ophthalmic, Glaucoma Agents)
- Cyclosporine, new generic for Restasis® (Ophthalmic, Anti-Inflammatory/Immunomodulators-Type) **Closed Class**

PDL Phase II – Annual Review: Classes with updates

Analgesics

- Antimigraine Agents
- Antimigraine Agents Other (**Potential new Closed Class**)
- Non-Steroidal Anti-Inflammatory Drugs (NSAID) (includes Cox-2 inhibitors and topical agents)
- Opioid Dependency Treatment Agents (**Closed Class**) (includes oral buprenorphine)
- Opioids: Short Acting (includes combination drugs and lozenges)

Antibiotics / Anti-Infectives

- Antifungals (oral)
- Gastrointestinal
- Quinolones (Second and Third Generations)

Antivirals

- Antivirals for Influenza

Cardiac

- Anticoagulants (*includes oral agents, low molecular weight heparins & Factor XA Inhibitors*) (Closed Class)
- Platelet Aggregation Inhibitors

Central Nervous System

- Antihyperkinesia/CNS Stimulants (Closed Class)
- Multiple Sclerosis Agents (Potential new Closed Class)
- Antipsychotics (Potential new Closed Class, Oral; long acting injectable is currently a Closed Class)
- Neuropathic Pain
- Smoking Cessation Agents

Dermatologic Agents (Topical)

- Acne Agents (*includes benzoyl peroxide, clindamycin, retinoids & combinations*)

Endocrine and Metabolic Agents

- Bone Resorption Suppression and Related Agents (*includes bisphosphonates, calcitonin and others*)
- Hypoglycemics: Incretin- mimetics- Exenatide (*includes DPPIV & combination*) (Closed Class)
- Hypoglycemics: Insulins
- Hypoglycemics: Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor (Closed Class)
- Hypoglycemics: Thiazolidinediones

Immunological Agents

- Self-administered Cytokine & CAM Antagonists with Related Agents including Methotrexate (*all indications: Rheumatoid Arthritis (RA), Juvenile Idiopathic Arthritis (JIA), Ankylosing Spondylitis (AS), Plaque Psoriasis, Psoriatic Arthritis (PsA), Crohn's Disease (CD), Ulcerative Colitis, Cryopyrin-Associated Periodic Syndromes (CAPS)*) (Closed Class)

PDL Phase II – Annual Review

Therapeutic Classes without Significant Updates (reviewed by the Department)

Analgesics

- Opioids: Long Acting

Antibiotics / Anti-Infectives

- Antibiotics (topical)
- Cephalosporins (Second and Third Generations)
- Ketolides & Macrolides (Adult and Pediatric)
- Quinolones (Otic)

Antivirals

- Antivirals for Herpes (HSV)

Blood Modifiers

- Antihyperuricemics
- Erythropoiesis Stimulating Proteins

Central Nervous System

- Alzheimer's Agents (Cholinesterase Inhibitors & NMDA Receptor Antagonist)
- Skeletal Muscle Relaxants

Contraceptives

- Long-Acting Reversible Contraceptives (LARCS) (*includes long-acting IUDs & injectable*)

Dermatologic Agents (Topical)

- Antifungal Agents, Topical
- Antivirals, Topical
- Psoriasis Agents
- Rosacea Agents

Endocrine and Metabolic Agents

- Androgenic Agents
- Estrogens (vaginal and oral)
- Hypoglycemics: Alpha-Glucosidase Inhibitors
- Hypoglycemics: Meglitinides
- Hypoglycemics: Metformins
- Hypoglycemics: Sulfonylureas
- Pancreatic Enzymes
- Progestational Agent (Potential new Closed Class)

Confidential Meeting (Pricing Information Discussion)

P&T Committee Members & DMAS Staff

Criteria Discussion of Phase I New Drugs

P&T Committee Members

Criteria Discussion of Phase II Drugs

P&T Committee Members

**Criteria discussions will be held for classes only if deemed PDL eligible by the P&T Committee during Drug Class Discussions.*

Next Meeting – September 15, 2022 (tentative)

Chair